Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors

K. Ishibashi T. Tokumoto, H. Shirakawa, K. Hashimoto, K. Ikuta, N. Kushida, T. Yanagida, K. Shishido, K. Aikawa, H. Toma, N. Inoue, O. Yamaguchi, K. Tanabe, T. Suzutani. Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors.
Transpl Infect Dis 2011: 13: 318–323. All rights reserved

[1]  W. Britt,et al.  Glycoprotein N subtypes of human cytomegalovirus induce a strain-specific antibody response during natural infection. , 2009, The Journal of general virology.

[2]  K. Hashimoto,et al.  Strain-specific seroepidemiology and reinfection of cytomegalovirus. , 2008, Microbes and infection.

[3]  G. Segoloni,et al.  Monitoring of human Cytomegalovirus infection by antigenemia and viremia in the first 100 days following renal transplantation and relation to antiviral strategies. , 2008, Minerva medica.

[4]  B. Mayer,et al.  CMV‐hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta‐analysis , 2007, Clinical transplantation.

[5]  N. Inoue,et al.  Association of the outcome of renal transplantation with antibody response to cytomegalovirus strain-specific glycoprotein H epitopes. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  R. Khanna,et al.  Cross‐reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H , 2004, European journal of immunology.

[7]  A. Åsberg,et al.  Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  M. Menzies,et al.  Ex Vivo Profiling of CD8+-T-Cell Responses to Human Cytomegalovirus Reveals Broad and Multispecific Reactivities in Healthy Virus Carriers , 2003, Journal of Virology.

[9]  P. Griffiths,et al.  Definitions of cytomegalovirus infection and disease in transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  B. Plachter,et al.  An antigen fragment encompassing the AD2 domains of glycoprotein B from two different strains is sufficient for differentiation of primary vs. recurrent human cytomegalovirus infection by ELISA , 2001, Journal of medical virology.

[11]  J. Garcia-conde,et al.  Lack of association between the kinetics of human cytomegalovirus (HCMV) glycoprotein B (gB)‐specific and neutralizing serum antibodies and development or recovery from HCMV active infection in patients undergoing allogeneic stem cell transplant , 2001, Journal of medical virology.

[12]  A. Meyerhans,et al.  LEVELS OF VIRUS-SPECIFIC CD4 T CELLS CORRELATE WITH CYTOMEGALOVIRUS CONTROL AND PREDICT VIRUS-INDUCED DISEASE AFTER RENAL TRANSPLANTATION1 , 2001, Transplantation.

[13]  W. Britt,et al.  Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity , 2001, The New England journal of medicine.

[14]  F. Pica,et al.  Neutralizing antibody response against human cytomegalovirus in allogeneic bone marrow-transplant recipients. , 1999, The Journal of infectious diseases.

[15]  H. Einsele,et al.  Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. , 1998, The Journal of infectious diseases.

[16]  J. Gómez-Moreno,et al.  Infection in organ-transplant recipients. , 1998, The New England journal of medicine.

[17]  W. Britt,et al.  Human cytomegalovirus glycoproteins. , 1996, Intervirology.

[18]  A. Messori,et al.  Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta-analysis. , 1994, Bone marrow transplantation.

[19]  M. Mach,et al.  Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. , 1992, The Journal of general virology.

[20]  S. Riddell,et al.  Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. , 1991, Blood.